Posts

Foghorn cuts 40% of staff after ending Lilly cancer programs

on
On October 1, 2026, Foghorn Therapeutics said it and Eli Lilly would stop advancing FHD-909 (also called LY4050784), an experimental SMARCA2 inhibitor, after reviewing Phase 1 dose-escalation data. The results did not show enough efficacy to move the drug into an expansion phase. The companies will also discontinue work on a related selective SMARCA2 degrader and do not expect further collaboration activities. Foghorn plans to cut about 40% of its workforce, leaving roughly 65 employees. It says the restructuring and pipeline reprioritization should extend its cash runway into the second half of 2029. Foghorn is redirecting resources toward its other programs, including EP300 and CBP degraders, an oral immunology and inflammation program, and its induced-proximity platform. The setback follows Foghorn’s earlier decision to stop developing FHD-286 after disappointing results in a leukemia trial. Sources: Foghorn Therapeutics Provides First Quarter 2026 ... Foghorn lays off...

BMS fibrosis-trial death raises liver-safety questions, but cause remains uncertain

on

CMS finalizes GLOBE model to link some Part B drug rebates to international prices

on

Varda raises $251 million to scale pharmaceutical processing in space

on

Lilly’s amylin–Zepbound combination shows up to 23.3% weight loss

on

Mironid begins dosing in first-in-human ADPKD drug trial

on

Merck’s anti-TL1A drug shows promising Phase 2b results in hidradenitis suppurativa

on

Ceribell wins FDA clearance for new EEG trending and analysis features

on

Recent U.S. news: HR-positive/HER2-negative breast cancer

on

KOL Insight: NSCLC Targeted Therapies — key takeaways

on

Kither Biotech begins patient dosing in KIT2014 COPD trial

on

Newly public biotechs are having a strong—but uneven—2026

on

Amgen reports promising Phase 2 results for skin-focused lupus antibody

on